The safety of orphan drugs is hard to monitor as they target rare diseases afflicting small patient populations. However, an initiative led by the SFDA aims to improve this.

Orphan drug monitoring emerges as a critical lifeline for rare diseases, offering hope to patients with uncommon medical conditions.